CYN154806

About the Target

CYN154806, a cyclic octapeptide, is a potent and selective somatostatin SST2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant SST2, SST1, SST3, SST4 and SST5 receptors respectively. The mapped target for this entry is Somatostatin receptor 2 (SSTR2). This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. In practical terms, this makes the product most relevant to experiments that need a defined and reversible way to perturb biology over short time scales.

Research Context

As an antagonist-format peptide, it is well suited to experiments that test pathway dependence, receptor blockade, and the extent to which a phenotype requires ongoing target signaling. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses.

• pair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible
• compare responses across cell states or model systems with different receptor abundance
• distinguish primary target engagement from downstream adaptation during longer incubations

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

The standard product format is most useful for reproducible baseline experiments, matched comparative studies, and workflows that need a consistent reagent across assay repeats. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.